Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Clavulanic Acid; Clavulanic Acids; Minocycline; Sulbactam; Sultamicillin; Tigecycline

Criteria

Inclusion Criteria:

• Clinical diagnosis of complicated skin or skin structure infection

• Male or female, 18 years or older

• Need for intravenous treatment for 4 to 14 days

Exclusion Criteria:

• Skin infection that can be treated by surgery & wound care alone

• Diabetic foot ulcers or bedsores where the infection is present longer than 1 week

• Poor circulation such that amputation of the infected site is likely within a month Other exclusions apply